- ANGLE, the specialist medtech company, welcomes new research which supports the potential use of the company's Parsortix cell separation technology.

This research details the use of Parsortix as part of a simple blood test, to diagnose and monitor patients with prostate cancer. The research will be presented during the National Cancer Research Institute annual conference on 6-9 November, Using Parsortix, scientists at the Barts Cancer Institute at Queen Mary University were able to capture a very specific subset of circulating tumour cells (CTCs) from prostate cancer patient blood samples.

These CTCs, which cannot be captured by traditional systems, are linked to the spread of the disease and as such could potentially be used, in future, to stage the severity of the prostate cancer and thereafter as a means of monitoring the patient.

Story provided by